KR20210091714A - 엑소좀-표적 이중 특이적 항체 - Google Patents

엑소좀-표적 이중 특이적 항체 Download PDF

Info

Publication number
KR20210091714A
KR20210091714A KR1020217014855A KR20217014855A KR20210091714A KR 20210091714 A KR20210091714 A KR 20210091714A KR 1020217014855 A KR1020217014855 A KR 1020217014855A KR 20217014855 A KR20217014855 A KR 20217014855A KR 20210091714 A KR20210091714 A KR 20210091714A
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
ala
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217014855A
Other languages
English (en)
Korean (ko)
Inventor
매튜 케이. 로빈슨
마이클 존 모린
Original Assignee
이뮤놈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤놈 인코포레이티드 filed Critical 이뮤놈 인코포레이티드
Publication of KR20210091714A publication Critical patent/KR20210091714A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217014855A 2018-10-17 2019-10-17 엑소좀-표적 이중 특이적 항체 Ceased KR20210091714A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746862P 2018-10-17 2018-10-17
US62/746,862 2018-10-17
PCT/US2019/056698 WO2020081786A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Publications (1)

Publication Number Publication Date
KR20210091714A true KR20210091714A (ko) 2021-07-22

Family

ID=70284767

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217014855A Ceased KR20210091714A (ko) 2018-10-17 2019-10-17 엑소좀-표적 이중 특이적 항체

Country Status (12)

Country Link
US (1) US20210347895A1 (https=)
EP (1) EP3866851A4 (https=)
JP (2) JP7496818B2 (https=)
KR (1) KR20210091714A (https=)
CN (1) CN113423425A (https=)
AU (1) AU2019359877A1 (https=)
BR (1) BR112021007469A2 (https=)
CA (1) CA3116560A1 (https=)
IL (1) IL282355A (https=)
MX (1) MX2021004036A (https=)
SG (1) SG11202103812RA (https=)
WO (1) WO2020081786A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501062A (ja) 2018-10-02 2022-01-06 イムノーム、インコーポレイテッド Ｅｐｎ１を標的とする抗体
CN113754771A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×egfr的双特异性抗体
CN114354913B (zh) * 2021-12-31 2024-07-19 厦门大学 一种外泌体pd-l1糖基化检测方法
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
WO2023225613A2 (en) * 2022-05-18 2023-11-23 Immunome, Inc. Combination anti-epn1 and anti-pd-l1 antibody therapies
EP4630966A2 (en) * 2022-12-09 2025-10-15 The Regents of the University of California Intelligent design and engineering of proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP4141032B1 (en) * 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
RU2018105846A (ru) * 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
PT3433273T (pt) * 2016-03-25 2022-02-21 Biomunex Pharmaceuticals Moléculas de ligação a cd38 e pd-l1
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质

Also Published As

Publication number Publication date
CA3116560A1 (en) 2020-04-23
CN113423425A (zh) 2021-09-21
AU2019359877A1 (en) 2021-05-20
JP7496818B2 (ja) 2024-06-07
EP3866851A1 (en) 2021-08-25
US20210347895A1 (en) 2021-11-11
EP3866851A4 (en) 2022-11-02
IL282355A (en) 2021-05-31
JP2024123004A (ja) 2024-09-10
SG11202103812RA (en) 2021-05-28
BR112021007469A2 (pt) 2021-08-10
WO2020081786A1 (en) 2020-04-23
JP2022512734A (ja) 2022-02-07
MX2021004036A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
CN111406069B (zh) 抗ctla4抗体及其用途
TWI414532B (zh) 抗第１型類胰島素生長因子接受器之抗體及其之使用
CN102421802B (zh) 人源化的axl抗体
KR20210091714A (ko) 엑소좀-표적 이중 특이적 항체
CA2691159C (en) Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
WO2020043184A1 (zh) 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
JP2025069305A (ja) 抗ｄｌｌ３キメラ抗原受容体及びその使用
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
TWI743051B (zh) 抗-met抗體及其使用方式
CA3138956A1 (en) Humanized and chimeric monoclonal antibodies to cd47
JP2018530540A (ja) 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2021008523A1 (zh) 抗tigit抗体及其应用
JP2022501065A (ja) 抗ｋｌｒｇ１抗体
JP2025524386A (ja) 抗ｃｌｄｎ１８．２抗体を含む二重特異性抗体、並びにその医薬組成物及び使用
JP2019531337A (ja) 増殖因子を標的とする二機能性分子を使用したがんの治療方法
CN116457016A (zh) 用于治疗癌症患者的pd-1拮抗剂和lag3拮抗剂以及乐伐替尼或其药学上可接受的盐的组合疗法
KR20220050182A (ko) 항-cd22 항체 및 그의 용도
WO2024165030A1 (zh) 三特异性抗原结合分子及其应用
HK40060740A (en) Exosome-targeting bispecific antibodies
TW202613175A (zh) Cdh3結合蛋白及其用途
KR20250114286A (ko) 개과 악성종양에 대한 면역제
TW202540199A (zh) 靶向her2及her3之雙特異性四價抗體
TW202534086A (zh) 抗ｐｓｃａ抗體及其用途
HK40076989B (zh) 抗cd22抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000